# Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

> **NCT05570188** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Kunming Hope of Health Hospital**

## Conditions studied

- B-cell Lymphoma
- B-cell Leukemia

## Interventions

- **BIOLOGICAL:** anti-CD19 UCAR-NK cells

## Key facts

- **NCT ID:** NCT05570188
- **Lead sponsor:** Kunming Hope of Health Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The PI decides to stop.
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05570188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05570188, "Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05570188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*